Likewise, in the TOT-HER3 study, which tested the clinical and biological activity of a single dose of HER3-DXd in patients with treatment-naïve early luminal BC, the ORR was independent of baseline HER3 IHC and ERBB3 mRNA expression level [44]. This evidence concerns the gene ERBB3 and breast cancer.